Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Racthera Co. Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct art units and involve 3 distinct examiners. This indicates that the company's pharmaceutical research is being reviewed by multiple groups within the patent office. The presence of 3 pending office actions across 2 distinct art units suggests a portfolio that, while focused on biotechnology, touches on different regulatory or technical classifications handled by the USPTO.
MIANO, JOSEPH PAUL is the busiest examiner for the company, with 1 pending office action. Since the busiest examiner pending count is 1, the workload is evenly split across the 3 distinct examiners. Practitioners must manage multiple examination styles simultaneously to advance this portfolio. The involvement of 3 distinct examiners means that each of the 3 pending office actions will be subject to an independent review process. This requires a strategy that addresses the specific pharmaceutical examination standards applied by each individual examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| SMALL, KATHERINE R | 1 | 68.9% | +30.7% |
| CANDELARIA, JULIANA IRENE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724170 | NEURAL CREST CELL CULTURING METHOD AND PRODUCTION METHOD | MIANO, JOSEPH PAUL | — |
| 18569736 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | SMALL, KATHERINE R | — |
| 16970087 | Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same | CANDELARIA, JULIANA IRENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724170 | NEURAL CREST CELL CULTURING METHOD AND PRODUCTION METHOD | MIANO, JOSEPH PAUL | — |
| 18569736 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | SMALL, KATHERINE R | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724170 | NEURAL CREST CELL CULTURING METHOD AND PRODUCTION METHOD | MIANO, JOSEPH PAUL | — | §102§103 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18569736 | METHOD FOR PRODUCING CEREBRAL CORTICAL CELL PREPARATION DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | SMALL, KATHERINE R | 1633 | §103§112 | Non-Final OA | — | Pending | Dec 13, 2023 |
| 16970087 | Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same | CANDELARIA, JULIANA IRENE | 1600 | §112 | Final Rejection | — | Pending | Aug 14, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial